Chemoprevention of exprimental bladder cancer

✍ Scribed by Richard C. Moon; Carol J. Detrisac; Cathy F. Thomas; Gary J. Kelloff

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 465 KB
• Volume: 50
• Category: Article
• ISSN: 0730-2312
• DOI: 10.1002/jcb.240501326

✦ Synopsis

The chemopreventive efficacy of several compounds was evaluated in the N-butyl-N-(4-hydroxybuty1)nitrosamine (OH-BBN)-induced urinary bladder cancer model using C57BU6 x DBN2F1 (BDF) male mice. Compounds were administered in a defined semipurified diet (AIN-76-A) either as single agents or in combination. As single agents and at the doses employed, 2-a-difluoromethylornithine (DFMO), piroxicam, oltipraz, and sodium molybdate effectively inhibited the incidence of transitional cell carcinoma (TCC). 4-Hydroxyphenyl retinarnide (4-HPR) was ineffective.

Body weight gain and survival was not affected by the doses of agents used. Combinations of two agents which increased efficacy were 4-HPR + DFMO. DFMO + piroxicam, 4-HPR + oltipraz, and DFMO + oltipraz. Three-agent combinations which showed enhanced efficacy against TCC induction were 4-HPR + Na molybdate + DFMO. 4-HPR + DFMO + piroxicam, and 4-HPR + DFMO + oltipraz. Although the three-agent combinations were, for the most pan, no more effective than the twoagent combinations at the doses employed, all combination regimens significantly reduced bladder cancer incidence even when single agent administration did not.